Production and characterisation of novel pyocins active against Pseudomonas aeruginosa

Colonisation of the lungs of patients with cystic fibrosis by the bacterium Pseudomonas aeruginosa is the main
cause of mortality associated with this condition. The natural resistance of this pathogen to many commonly-used
antibiotics can make P. aeruginosa infections very difficult to treat in some patients and there is an urgent need
to develop new therapies. The aim of this project is to produce and test the ability of protein antibiotics to kill P.
aeruginosa clinical isolates. The ultimate goal of this work is to develop these protein antibiotics as novel
therapeutics for the treatment of P. aeruginosa infection.